MAPT and frontotemporal dementia: Recent experimental evidence has related Tau‐dependent FTD with dysregulation in eCB signaling [9], which may support the pharmacological modulation of certain proteins of this system (e.g., cannabinoid type‐2 [CB2] receptors) as a promising disease‐modifying therapy in this form of FTD [9, 10, 11].